Silence Therapeutics (SLN) Interest Expenses (2024 - 2025)
Silence Therapeutics (SLN) reported Interest Expenses of $160000.0 for Q4 2025, down 99.74% on a YoY basis from $61.4 million in Q4 2024, and down 99.74% sequentially from $61.4 million in Q4 2024.
Silence Therapeutics (SLN) Interest Expenses (2024 - 2025) Analysis & Trends
Silence Therapeutics (SLN) has 2 years of Interest Expenses data on file, last reported at $160000.0 in Q4 2025.
- For the quarter ending Q4 2025, Interest Expenses fell 99.74% year-over-year to $160000.0; the trailing twelve-month figure through Dec 2025 stood at $160000.0 (down 99.74% YoY), and the FY2025 full-year result was $80.4 million, up 30.87% from the prior year.
- Interest Expenses eased to $160000.0 in Q4 2025, from $61.4 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $61.4 million in Q4 2024 to a low of $160000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | Silence Therapeutics | 1.59 Bn | 1.45 Bn | 411,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 160,000.00 |
| Dec 31, 2025 | 160,000.00 |
| Dec 31, 2024 | 61.45 Mn |
| Dec 31, 2024 | 61.45 Mn |